ERBB2 and breast cancer: While resistance in HER2+ breast cancer has traditionally been attributed to oncogenic signalling rewiring within tumour cells, our findings suggest that anti-HER2 therapy may also influence CAFs, promoting the secretion of factors that support tumour cell survival under therapeutic pressure.